Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported earnings for its third fiscal quarter (ending September 30) of $0.20 versus a loss $-0.40 for the same period a year ago — a decline of -150%. For the latest four quarters through September 30, E.P.S. were $0.78 versus $-0.91 for the same period a year ago — a decline of -186%.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock enjoyed a very large increase of 5.3% on 11/6/24. The shares closed at $15.79. Moreover, this advance was accompanied by unusually high trading volume at 167% of normal. The stock has been weak relative to the market over the last nine months but has risen 7.1% during the last week.
Current PriceTarget Research Rating
ACAD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Acadia Pharmaceuticals has a poor Power Rating of 17 and a very low Appreciation Score of 14, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment